Overview of the insider sale
On March 30, 2026, John P. Schmid, a director of AnaptysBio (NASDAQ:ANAB), sold a total of 20,645 shares of the company’s common stock in multiple transactions that collectively amounted to $1.16 million. The individual tranches recorded prices that ranged from $55.7087 to $57.3989 per share.
Transaction breakdown
- 12,596 shares sold at a weighted average price of $55.7087.
- 7,527 shares sold at a weighted average price of $56.7002.
- 522 shares sold at a weighted average price of $57.3989.
After completing these sales, Schmid is recorded as directly holding 31,622 shares of AnaptysBio common stock.
Market context
At the time of reporting, AnaptysBio shares were trading at $56.73. That price represents a decline of roughly 13% over the past week while the stock has delivered a 199% return over the prior 12 months. Analyzing valuation, InvestingPro reported that the stock appears overvalued at current levels and offers 16 additional tips for ANAB to provide further context on the company’s financial position and market standing.
Corporate developments: spinoff, financing and buyback
In separate corporate activity, AnaptysBio confirmed plans to spin off First Tracks Biotherapeutics. First Tracks has obtained $80 million through a private placement. The distribution related to the spinoff is expected to occur on April 20, 2026. Under the distribution terms, shareholders of AnaptysBio on the record date will receive one share of First Tracks Biotherapeutics common stock for each share of AnaptysBio common stock held.
Concurrently, AnaptysBio’s Board of Directors has authorized a $100 million stock buyback program.
Analyst reactions
Following the spinoff announcement, Piper Sandler raised its price target for AnaptysBio to $95 while maintaining an Overweight rating, citing the successful launch of JEMPERLI and potential opportunities for ANB033. H.C. Wainwright reiterated a Buy rating and set a $66 price target on AnaptysBio after the spinoff news.
What the record shows
The insider sale, the financing for First Tracks Biotherapeutics, the scheduled distribution on April 20, 2026, and the $100 million buyback authorization are all documented corporate events. Analyst target changes from Piper Sandler and H.C. Wainwright are noted following the spinoff announcement. Reporting shows Schmid’s post-sale direct ownership as 31,622 shares.
This account sticks to the facts disclosed in company filings and analyst notes without adding interpretation beyond the recorded transactions and corporate actions.